Registration and abstract submissions for the 41st NSI Annual Meeting and General Assembly are now open!
Date: Friday, November 24, 2023
Time: 9.30 to 22.00
Location: Runde Auditorium, Domus Medica
Deadlines
Registration deadline:21st November 2023
Poster abstract to be considered for short talk deadline: 14th October (submission after deadline will only be posters)
Poster abstract deadline: 1st November 2023
Dinner fee deadline (350 NOK):23rd November 2023 [last year, very few people paid this fee. You can find the bank details in the nettskjema below.]
Please register and submit your abstract here: https://nettskjema.no/a/353037.
**Four (4) travel grants will be awarded for non-Oslo attendees**. A successful candidate must have an abstract as first author for the NSI yearly meeting. Responsible: Gunnveig Grødeland (gunnveig.grodeland@medisin.uio.no). Deadline: Same as Poster abstract deadline.
Abstract guidelines/dinner information etc. can be found in the Nettskjema link above.
Full program:
NSI Annual Meeting 2023 prizes
Congratulations to all the winners! As always the competition was tight, which is why some prizes were divided between two top candidates. Thank you all for the participation and remember to join the contest next year as well!
Best poster award:
Håvard T. Lindholm (abstract title: Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer)
Runa I. Løberg (abstract title: Generation of an immunoglobulin knock-in mouse to study gluten-specific T cell – B cell collaboration in celiac disease)
Best talk award:
Christopher Forcados (talk title: Targeting carbohydrates in adenocarcinomas: STn-CAR T cells)
NSI-Bogen research award:
Rasmus Iversen
NSI research award:
Eirini C. Giannakopoulou (article title: A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo)
Andreas H. Røssevold (article title: Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial)